ImCheck HP

Exploring uncharted territories in immunomodulation
Butyrophilins & Gamma-delta T cells

ImCheck Therapeutics is driving innovation in immune system modulation based on our unique know-how in the butyrophilin (BTN) and BTN-like (BTNL) superfamily of checkpoint molecules. We are designing the next generation of immunotherapeutic antibodies for the treatment of cancer, infectious disease, and autoimmune disease.

Latest news


ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation
Leadership & Corporate 
Read more
ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
Science & Medicine 
Read more
ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
Science & Medicine 
Read more

6th Cell Engager Therapeutics Summit

From  May 21, 2024  to  May 23, 2024 

Read more

Cytokine-based drug development Summit

From  May 21, 2024  to  May 23, 2024 

Read more

ASCO 2024

From  May 31, 2024  to  Jun 04, 2024 

Read more

STAY IN TOUCH WITH OUR LATEST NEWS

Subscribe to receive our press releases and related news